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ABSTRACT
Objective It has been hypothesised that the use 
of ACE inhibitors and angiotensin receptor blockers 
(ARBs) might either increase or reduce the risk of severe 
or lethal COVID-19. The findings from the available 
observational studies varied, and summary estimates 
are urgently needed to elucidate whether these drugs 
should be suspended during the pandemic, or patients 
and physicians should be definitely reassured. This 
meta- analysis of adjusted observational data aimed 
to summarise the existing evidence on the association 
between these medications and severe/lethal COVID-19.
Methods We searched MedLine, Scopus and preprint 
repositories up to 8 June 2020 to retrieve cohort or 
case–control studies comparing the risk of severe/fatal 
COVID-19 (either mechanical ventilation, intensive care 
unit admission or death), among hypertensive subjects 
treated with: (1) ACE inhibitors, (2) ARBs and (3) both, 
versus untreated subjects. Data were combined using a 
random- effect generic inverse variance approach.
Results Ten studies, enrolling 9890 hypertensive 
subjects were included in the analyses. Compared with 
untreated subjects, those using either ACE inhibitors or 
ARBs showed a similar risk of severe or lethal COVID-19 
(summary OR: 0.90; 95% CI 0.65 to 1.26 for ACE 
inhibitors; 0.92; 95% CI 0.75 to 1.12 for ARBs). The 
results did not change when both drugs were considered 
together, when death was the outcome and excluding 
the studies with significant, divergent results.
Conclusion The present meta- analysis strongly 
supports the recommendation of several scientific 
societies to continue ARBs or ACE inhibitors for all 
patients, unless otherwise advised by their physicians 
who should thus be reassured.
INTRODUCTION
With the spread of severe acute respiratory 
syndrome coronavirus 2 (SARS- CoV-2) pandemic, 
evidence is rapidly accumulating on the risk factors 
of severe COVID-19 and death. In the wake of 
some preliminary, unadjusted reports,1–4 indi-
viduals with pre- existing comorbidities such as 
hypertension, diabetes and cardiovascular diseases 
have been identified as those highly vulnerable.5 
Notably, such chronic conditions frequently require 
prescription of ACE inhibitors and angiotensin II 
receptor blockers (ARBs).6 Animal studies showed 
that ACE inhibitors and ARBs upregulate ACE2 
expression7 and, as coronaviruses bind their target 
cells through ACE2, concerns have been expressed 
that these therapies might facilitate infection with 
SARS- CoV-2 and increase the risk of severe or fatal 
COVID-19.6 8 In contrast, it has been suggested that 
ACE inhibitors and ARBs could benefit infected 
patients, as ACE2 converts angiotensin II (with 
known vasoconstrictive, proinflammatory and 
fibrotic effects) into angiotensin 1–7, which may 
protect lungs from acute injury, and upregulating 
ACE2 through therapy may enhance this process.9
In this uncertain scenario, some observational 
studies with multivariable analyses found no asso-
ciation between use of renin–angiotensin–aldo-
sterone system (RAAS) inhibitors and COVID-19 
severity,10–16 a few studies found a significant 
reduction in the risk of death or severe disease17 18 
and one study found a increased risk of mechan-
ical ventilation and admission to the intensive care 
unit (ICU).19 The magnitude of the association also 
varied across studies, which differed for patients’ 
characteristics, setting (inpatient or outpatient), 
population targeted by serological testing protocols 
and extent of measured confounding.
Summary estimates are urgently needed to eluci-
date whether these drugs, that are prescribed to 
tens of millions patients worldwide,20 should be 
suspended during the pandemic, or patients and 
physicians should be definitely reassured.7 We thus 
carried out a meta- analysis to summarise the existing 
evidence from adjusted analyses on the association 
between RAAS inhibitors and COVID-19.
METHODS
Bibliographic search, data extraction and quality 
assessment
We searched MEDLINE and Scopus databases, up 
to 11 May 2020, for studies evaluating the risk of 
severe and/or fatal COVID-19 among ACE inhib-
itors and/or ARBs users versus non- users. The 
following search strategy was adopted, without 
language restrictions: COVID-19 [Title/Abstract] 
OR Coronavirus [Title/Abstract] OR SARS- CoV-2 
[Title/Abstract] AND angiotensin* [Title/Abstract]. 
The reference lists of reviews and retrieved articles 
was also screened for additional pertinent papers. 
In the context of a public health emergency, there is 
urgency to make research findings available,21 and 
several relevant clinical data have been shared in 
public preprint repositories: we thus extended the 
search to include any relevant manuscript posted 
in MedRxiv. Inclusion criteria were: (A) cohort or 
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case–control design; (B) laboratory confirmation of SARS- CoV-2 
infection status through PCR assay of nasal or pharyngeal swab 
specimens; (C) available information on underlying comorbidi-
ties and pharmacological treatments at the time of COVID-19; 
and (D) data available to compare COVID-19 severity by RAAS 
treatment among hypertensive patients. Each included article 
was independently evaluated by two reviewers (MEF and CAM) 
who extracted the study characteristics and measures of effect. 
In case of discrepancies in data extraction, a third author was 
contacted (LM), and consensus was achieved through discussion.
Individual study quality was assessed using an adapted version 
of the Newcastle Ottawa Quality Assessment Scale, assessing 
the comparability across groups for confounding factors, the 
appropriateness of outcome assessment, length of follow- up and 
missing data handling and reporting.22
Data analysis
Data were combined using a random- effect generic inverse vari-
ance approach23 in order to account for between- study hetero-
geneity. Missing SEs were computed from 95% CIs following 
standard Cochrane methodology. If a paper reported the results 
of different multivariable models, the most stringently controlled 
estimates (those from the model adjusting for more factors) were 
extracted. If different models controlled for the same number of 
covariates, the model containing the most clinically meaningful 
covariates was used for the analysis.24
Between- study heterogeneity was quantified using the I2 
statistic. Potential publication bias was assessed graphically, 
using funnel plots (displaying the Relative Risks from individual 
comparisons versus their precision (1/SE). Given that the total 
number of publications included for each outcome was <10, 
we could not use formal tests for funnel plot asymmetry: in 
such cases, the power is too low to distinguish chance from real 
asymmetry.
The units of the meta- analysis were single comparisons of: 
(A) ACE inhibitors, (B) ARBs users and (C) both ACE inhibitors 
and ARBs users, versus non users, in predicting: (1) severe/lethal 
COVID-19 (presence of either ICU admission, mechanical venti-
lation or death) and (2) lethal COVID-19. When a study only 
reported separate estimates for ACE inhibitors or ARBs users, or 
for the different outcomes included in the definition of severe/
lethal COVID-19 (eg, ICU admission and mechanical ventilation 
separately), the overall estimate of risk was computed from the 
separate relative risks using the fixed- effect model for generic 
inverse variance outcomes.24
All meta- analyses were performed using RevMan software, 
V.5.3 (The Cochrane Collaboration, 2019).
Ethics
The informed consent was not required, as the study did not 
enrol human subjects.
RESULTS
Of the 553 papers initially retrieved, five case–control and five 
cohort studies were included in the analyses10–19 (figure 1).
Overall, the studies included 9890 hypertensive subjects; four 
studies included only COVID-19 symptomatic patients requiring 
hospitalisation13 16–18 (table 1). Six studies were carried out in 
Europe,10–12 14 16 17 two in the USA15 19 and two in China.13 18 The 
mean age ranged from 58 to 69 years, and the sample size ranged 
from 20517 to 6272.14
The methodological characteristics of the included studies are 
summarised in table 2: the selection of the cohort of patients, the 
ascertainment of the exposure and the evaluation of the compa-
rability of subjects were adequate in all studies, while 8 out of 
10 adequately addressed the items pertaining to outcome assess-
ment and follow- up (length and missing data). One study had a 
high risk of misclassification bias, as the proportions of hyper-
tensive subjects treated with ACE inhibitors (16.4%) or ARBs 
(13.2%) were particularly low.19
Risk of severe/lethal COVID-19
A total of five studies, enrolling 7489 hypertensive patients, 
were included in the meta- analysis comparing the risk of severe/
lethal COVID-19 between ACE inhibitors users versus non- 
users10 14 15 17 19 (table 3, figure 2). Overall, the risk of severe 
or lethal disease was comparable among treated and untreated 
patients (summary OR: 0.90; 95% CI 0.65 to 1.26). Two studies 
showed significant results, with opposite direction. The first 
included 682 hypertensive subjects and showed an increased 
risk of severe illness among the 112 patients treated with ACE 
inhibitors.19 The second enrolled 105 hypertensive subjects and 
reported a lower risk among the 38 treated patients.17 Excluding 
one or both of these studies did not change the results, which 
remained non- significant (all p>0.05).
Five studies, enrolling 7462 hypertensive subjects, were 
included in the meta- analysis comparing the risk of severe illness 
between ARBs users and non- users10 13–15 19 (table 3, figure 3). 
All of them showed non- significant differences between treated 
and untreated patients, with a summary OR of 0.92; 95% CI 
0.75 to 1.12.
When the above antihypertensive treatments were consid-
ered together (five studies, enrolling 11 334 hypertensive 
patients),10 11 14 15 19 the risk of developing severe COVID-19 
was again comparable between treated and untreated patients 
(summary OR: 1.00; 95% CI 0.84 to 1.18; figure 4).
Risk of death from COVID-19
The risk of death among RAAS inhibitors users versus non- 
users was compared in four studies, including a total of 2412 
Figure 1 PRISMA 2009 flow diagram. PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses.
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hypertensive subjects.10 12 16 18 Overall, no differences in risk 
emerged between the two groups, with a summary OR of 
0.88 (95% CI 0.68 to 1.14; table 3, figure 5). A single study 
from China, enrolling 1128 hospitalised hypertensive patients, 
showed a significant risk reduction among treated subjects18; 
when its results were excluded from the analyses, the overall 
estimates did not change (pooled OR 0.95; 95% CI 0.76 to 
1.18). Another study25 assessed the risk of death among ACE 
inhibitors/ARBs users versus non users and was initially included 
in the meta- analysis. However, this study was later retracted26; 
thus, it was excluded from the main analyses and included into 
a sensitivity analysis: with or without the study, the summary 
estimate did not change (pooled OR 0.85; 95% CI 0.81 to 1.03).
DISCUSSION
Two main findings emerge from the present meta- analysis, which 
included the adjusted estimates of 10 observational studies and 
Table 1 Characteristics of the included studies
N First author Journal Country Study design















- up Extracted outcome(s) Method for adjustment
1 Bean17 Submitted
(MedRxiv)
UK Cohort 205 (53) 105 (38) 63.0 (20.0) 51.7 7 days Severe/lethal COVID-19
(ICU and death).
Logistic regression 
adjusted for age, gender 
and comorbidities.
2 Bravi10 Submitted Italy Case–control 1603 (192) 543 (450) 58.0 (20.9) 47.3 24 days (1) Severe/lethal 
COVID-19 (mech. 
ventilation, ICU and 
death); (2) death.
Logistic regression 
adjusted for age, gender 
and comorbidities
3 de Abajo11 The Lancet Spain Case–control 1139 (393) * 6261 (3950)* 69.1 (15.4) 61.0 – Severe COVID-19 
(hospital admission).
Logistic regression 




4 Giorgi Rossi12 Submitted
(MedRxiv)
Italy Cohort 2653 (217) 430 (108) 63.2 50.1 14 days Death. Cox proportional hazard 
analysis adjusted for age, 




China Case- control 511 (38†) 78 (22) 65.2 (10.7) 55.2 NR Severe/lethal COVID-19
(dyspnoea, resp. rate 
≥30/min,
SaO2 ≤93%, mech. 
ventilation).
Logistic regression 
adjusted for gender and 
medications.
6 Mancia14 NEJM Italy Case–control 6272 (617) 3586 (1844) 68.0 (13.0) 63.2 – Severe/lethal COVID-19
(ICU and death),
Logistic regression 




Multicountry Cohort 8910 (515) 2346 (1326) 49.0 (16.0) 60.0 40 days Death. Logistic regression 





USA Cohort 1735 (272) 682 (202) 64.0 (14.0) 58.5 NR Severe/lethal COVID-19
(ICU and mech. 
ventilation).
Logistic regression 
adjusted for age, gender 
and comorbidities.
9 Reynolds15 NEJM USA Case- control 5894 (1002) 2573 (2141) 64.0 (15.6) 50.8 – Severe/lethal COVID-19 
(mech. ventilation, ICU 
and death).
Analysis propensity 
score- matched for 
age, gender, race, BMI, 
smoke, comorbidities and 
medications.
10 Tedeschi16 Clin Infect
Dis
Italy Cohort 609 (179) 311 (175) 68.0 (18.5) 68.0 6 days Death. Cox proportional hazard 
analysis adjusted for age, 
gender and comorbidities.
11 Zhang18 Circ Res China Cohort 1128 (99) 1128 (188) 64.0 (9.0) 53.3 28 days Death. Analysis propensity 
score- matched for age, 
gender, comorbidities and 
in- hospital therapy.
*Cases were COVID-19 patients; controls were SARS- CoV-2 negative subjects extracted from primary healthcare databases: as such, the number of hypertensive subjects includes both cases and controls and is higher 
than the number of COVID-19 patients.
†Number of patients with severe COVID-19 among only those with hypertension.
‡Included only in sensitivity analyses.
ARBs, Angiotensin receptor blockers; ICU, intensive care unit; mech., mechanical; NR, not reported; SARS- CoV-2, severe acute respiratory syndrome coronavirus 2.
Table 2 Methodological quality of the included studies according to 
the Newcastle Ottawa Scale
Selection Comparability Outcome
(max. score 4) (max. score 2) (max. score 3)
Bean17 4 2 3
Bravi10 4 2 3
de Abajo11 4 2 3
Giorgi Rossi12 4 2 3
Liu13 4 2 1
Mancia14 4 2 3
Mehta19 3 2 1
Reynolds15 4 2 3
Tedeschi16 4 2 3
Zhang18 4 2 3
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almost 10 000 hypertensive subjects: first, no significant differ-
ences in the risk of developing severe or fatal COVID-19 were 
observed between the subjects treated with either ACE inhibi-
tors or ARBs, as compared with non- users. Second, and impor-
tantly, the results did not change after the exclusion of the three 
studies, which reported either a significantly higher or lower risk 
of severe illness among treated patients.
The present findings provide solid evidence from properly 
adjusted estimates across different countries on the absence 
of risk from RAAS inhibitors treatment during the pandemic, 
strongly supporting the statements of several experts27 28 and 
scientific societies, including the European Medicines Agency,29 
the European Society of Cardiology30 and the American Heart 
Association,31 who recommend continuation of ARBs or ACE 
inhibitors medication. Although the present findings do not 
support the hypothesis of a beneficial effect from therapy during 
the necessary time required for randomised data to come, 
patients and physicians can be reassured.
Some limitations should be considered when interpreting 
the present findings. First, two meta- analyses showed an 
intermediate- to- high level of heterogeneity. However, a certain 
degree of heterogeneity across studies was inevitable, given the 
large variation in terms of setting and baseline patients charac-
teristics. Also, when the analyses were repeated adopting a fixed 
approach, none of the results substantially differed (except for 
CIs, which were typically tighter). Second, although all studies 
(with a single exception)13 provided analyses at least adjusted for 
age, gender and several underlying comorbidities, some extent of 
residual confounding cannot be completely ruled out, as for any 
observational study.32 Third, as shown in the funnel plots in the 
supplementary online Figures S1- S4, no meta- analysis included 
more than five studies, thus it was not possible to perform a 
meaningful evaluation of publication bias. However, given the 
public health relevance of these data, it is unlikely that non- 
significant findings—with reassuring implications—have been 
withheld. Rather, it is certain that large dataset will be available 
soon. Given the urgency for millions of patients, we decided not 
to wait, but the present meta- analysis will have to be updated as 
new adjusted analyses are published. Finally, the risk of selective 
inclusion bias, due to the presence of multiple effect estimates 
that can be extracted from individual studies,33 is likely to be 
low, as only one of the included studies reported more than an 
adjusted estimate,18 and the results of the meta- analysis including 
the alternate estimate of effect were unchanged (pooled OR of 
death 0.88; 95% CI 0.68 to 1.13).
Acknowledging these caveats, the present meta- analysis, based 
on 10 studies and almost 10 000 hypertensive subjects, did not 
find any association between COVID-19 severity or mortality 
and treatment with ARBs, ACE inhibitors or both, strongly 
supporting the recommendation of several scientific societies 
to continue ARBs or ACE inhibitors medication for all patients, 
unless otherwise advised by their physicians, who should thus 
be reassured.
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Table 3 Risk of severe/fatal COVID-19 or death among hypertensive 
subjects treated with RAAS inhibitors versus untreated subjects, overall 






OR (95% CI) P value I2, %
1. Severe/fatal COVID-19* 
(in users vs non users):
ACE inhibitors 
only10 14 15 17 19
5 (7489) 0.90 (0.65 to 1.26) 0.6 80
ARBs only10 13–15 19 5 (7462) 0.92 (0.75 to 1.12) 0.4 25
ARBs/ACE 
inhibitors10 11 14 15 19
5 (11 334) 1.00 (0.84 to 1.18) 0.9 50
2. Death from COVID-19 
(in users vs non users):
a. Main analysis:
ARBs/ACE 
inhibitors10 12 16 18
4 (2412) 0.88 (0.68 to 1.14) 0.3 24
b. Sensitivity analysis:†
ARBs/ACE 
inhibitors10 12 16 18 25
5 (4758) 0.85 (0.71 to 1.03) 0.10 12
All meta- analyses are based on a generic inverse variance approach.
*Including admission into intensive care unit, need for mechanical ventilation or 
death.
†Including one retracted study.25 26
ARBs, angiotensin receptor blockers; RAAS, renin–angiotensin–aldosterone.
Figure 2 Risk of severe/lethal COVID-19 among ACE inhibitors users 
versus non- users.
Figure 3 Risk of severe/lethal COVID-19 among ARB inhibitors users, 
versus non- users. ARBs, angiotensin receptor blockers.
Figure 4 Risk of severe/lethal COVID-19 among ACE inhibitors/ARBs 
users versus non- users. ARBs, angiotensin receptor blockers.
Figure 5 Risk of death among ACE inhibitors/ARBs users versus non- 
users. ARBs, angiotensin receptor blockers.
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Key messages
What is already known on this subject?
 ► Some preliminary, unadjusted reports on severe acute 
respiratory syndrome coronavirus 2 positive subjects showed 
an increased mortality and morbidity among hypertensive 
patients, who were frequently treated with ACE inhibitors 
or angiotensin receptor blockers (ARBs). Recently, some 
observational studies with multivariable analyses found 
no association between these medications and COVID-19 
severity, a few studies found a significant reduction in the risk 
of death or severe disease and one study found a increased 
risk of mechanical ventilation and admission to the intensive 
care unit. The magnitude of the association also varied across 
studies, which differed for patients’ characteristics, setting 
(inpatient or outpatient), population targeted by serological 
testing protocols and extent of measured confounding.
What might this study add?
 ► This meta- analysis is based on 10 adjusted observational 
studies (enrolling almost 10 000 hypertensive subjects), from 
different countries, and provides the first summary estimate 
on the association between ACE inhibitors or ARBs use 
and COVID-19 severity or mortality. All analyses showed a 
comparable risk of severe or fatal illness among treated and 
untreated subjects, either considering ACE inhibitors or ARBs 
separately, or combined.
How might this impact on clinical practice?
 ► Given that ACE inhibitors and ARBs are prescribed to tens 
of millions patients worldwide, summary estimates were 
strongly needed to elucidate whether these drugs should be 
suspended during the pandemic, or patients and physicians 
should be definitely reassured. These findings strongly 
support the recommendation of several scientific societies to 
continue ARBs or ACE inhibitors medication for all patients, 
unless otherwise advised by their physicians.
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